Development of meloxicam potassium-containing co-spray-dried inhalation powder with sodium stearate

Benke, Edit and Szabó-Révész, Piroska and Ambrus, Rita (2021) Development of meloxicam potassium-containing co-spray-dried inhalation powder with sodium stearate. ACTA PHARMACEUTICA HUNGARICA, 91 (2). pp. 75-82. ISSN 0001-6659

Preview

Text 46-Article Text-1233-1-10-20211121.pdf Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (2MB) | Preview

Abstract

Pulmonary drug delivery (PDD) has potential for both local and systemic therapy. Our research group is focus- ing on the development of dry powder inhalation (DPI) systems for PDD due to their beneficial properties. Although there is not yet a marketed inhalation product for non-steroidal anti-inflammatory drugs (NSAIDs), their therapeutic use in sev- eral lung diseases is well established and successful DPI developments have been performed with them. Sodium stearate (NaSt) is a promising excipient for DPI development, but its role in NSAIDs has not yet been investigated. Thus, the aim was to study DPI samples produced by co-spray-drying, applying meloxicam potassium (MXP) as an NSAID drug, and different concentrations (0-2 w/w%) of NaSt. Physicochemical investigations, in vitro lung deposition, and in vitro drug release measurements were performed. It can be stated that co-spray-drying of MXP with NaSt resulted in remarkable morphological differences by increasing the concentration of NaSt, which had a positive effect on cohesive work. Further- more, applying of NaSt accelerates the dissolution in simulated lung fluid (SLF). NaSt as excipient has a future for the formulation of the DPI systems because there are in the development focus the attaintment of the higher FPF values and improvement of dissolution in SLF.

Actions (login required)

Edit Item